Aliskiren | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Aliskiren
HEALTH CANADA PATENTS

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Aliskiren

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

8 API Suppliers, 4 USDMF, 3 EU WC, 3 NDC API, 4 Listed Suppliers

8 API Suppliers
4 USDMF
3 EU WC
3 NDC API
4 Listed Suppliers

INTERMEDIATES

5 Intermediates Suppliers

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

24 FDF Dossiers, 20 FDA Orange Book, 4 Europe

24 FDF Dossiers
20 FDA Orange Book
4 Europe

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE, TABLET;ORAL - EQ 300MG BASE, TABLET;ORAL - EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 300MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 150MG BASE
TABLET;ORAL - EQ 300MG BASE
TABLET;ORAL - EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 300MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 2 Seqens, 4 DKSH, 2 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 1 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 22 BASF, 10 Corel Pharma Chem, 2 DFE Pharma, 1 Finar, 8 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 16 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 2 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 10 Roquette, 6 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 9 Sigachi Industries, 2 The Dow Chemical Company, 2 Ulanqab Kema New Material, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

44 Coating Systems & Additives, 34 Fillers, Diluents & Binders, 28 Controlled & Modified Release, 25 Direct Compression, 19 Disintegrants & Superdisintegrants, 19 Thickeners and Stabilizers, 17 Granulation, 14 Solubilizers, 13 Lubricants & Glidants, 11 Co-Processed Excipients, 8 Film Formers & Plasticizers, 7 Topical, 6 Chewable & Orodispersible Aids, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Taste Masking, 4 Emulsifying Agents, 4 Parenteral, 2 Rheology Modifiers

44 Coating Systems & Additives
34 Fillers, Diluents & Binders
28 Controlled & Modified Release
25 Direct Compression
19 Disintegrants & Superdisintegrants
19 Thickeners and Stabilizers
17 Granulation
14 Solubilizers
13 Lubricants & Glidants
11 Co-Processed Excipients
8 Film Formers & Plasticizers
7 Topical
6 Chewable & Orodispersible Aids
5 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
4 API Stability Enhancers
4 Taste Masking
4 Emulsifying Agents
4 Parenteral
2 Rheology Modifiers

DIGITAL CONTENT

13 NEWS #PharmaBuzz

13 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 4 Finished Drug Prices, 1 Annual Reports

3 US Medicaid Prescriptions
4 Finished Drug Prices
1 Annual Reports

MARKET PLACE

1 APIs, 1 FDF Dossiers

1 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

14 US Patents, 2 Health Canada Patents

14 US Patents
2 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 2Gowling Strathy & Henderson

filter Patent Reset all filters

2 All

01 22147056

filter Product Reset all filters

2 All

01 2Aliskiren

filter Dosage Reset all filters

2 All

01 2Film-Coated Tablets

filter Exp Date Reset all filters

2 All

01 22015-04-13

Product Main Page

01

Gowling Strathy & Henderson

Aliskiren

euroPLX 86 Munich

Not Confirmed

Gowling Strathy & Henderson

Canada

euroPLX 86 Munich

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Brand Name : RASILEZ

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 150mg

Dosage Form : Film-Coated Tablets

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowling Strathy & Henderson

Aliskiren

euroPLX 86 Munich

Not Confirmed

Gowling Strathy & Henderson

Canada

euroPLX 86 Munich

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Brand Name : RASILEZ

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 300mg

Dosage Form : Film-Coated Tablets

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?